SGS Expands Bioanalytical Testing Capabilities in North America with Acquisition of CMIC, INC.

SGS, a global leader in testing, inspection, and certification services, has announced its acquisition of CMIC, INC., a bioanalytical testing service provider based in Chicago, Illinois. The deal, finalized on June 3, 2026, involves an undisclosed amount and is expected to significantly enhance SGS's laboratory network in North America. CMIC, INC. specializes in supporting pharmaceutical and biotech manufacturers with bioanalytical testing services, facilitating the market entry of specialized biologics and therapeutics.

CMIC, INC. operates a 27,000 square foot Good Laboratory Practice (GLP)-compliant facility that provides bioanalysis throughout both pre-clinical and clinical phases of drug development. The company has established itself as a key player in the North American bioanalytical testing market since its inception in 2010. This acquisition follows SGS's recent purchase of another U.S.-based bioanalytical testing service provider, further solidifying its presence in this growing sector.

The strategic rationale behind the acquisition aligns with SGS's broader objectives, particularly its Strategy 27 initiative, which aims to double North American sales by 2027. The bioanalytical testing market is witnessing robust growth driven by increasing demand for advanced testing capabilities, particularly for biologics and emerging therapies such as oligonucleotides. As regulatory scrutiny intensifies, pharmaceutical companies are increasingly outsourcing bioanalytical testing to specialized providers, creating a favorable environment for SGS's expansion.

With over 30 years of experience in supporting the North American pharmaceutical industry, SGS is well-positioned to leverage its extensive laboratory network, which includes more than 20 facilities across 11 countries. The addition of CMIC, INC. enhances SGS's capabilities in delivering high-quality bioanalytical data, essential for demonstrating the safety and efficacy of complex therapies in compliance with regulatory standards.

The acquisition of CMIC, INC. not only strengthens SGS's service offerings but also underscores the growing trend of consolidation within the bioanalytical testing sector. As companies seek to enhance their capabilities and respond to evolving market demands, strategic acquisitions like this one are likely to continue shaping the landscape of the testing, inspection, and certification industry. The move is expected to further position SGS as a leader in the global bioanalytical testing market, ultimately benefiting pharmaceutical and biotech clients as they navigate the complexities of drug development and regulatory compliance.